WO2006066214A3 - Use of flagellin in the immunotherapy of yersinia pestis - Google Patents

Use of flagellin in the immunotherapy of yersinia pestis Download PDF

Info

Publication number
WO2006066214A3
WO2006066214A3 PCT/US2005/045954 US2005045954W WO2006066214A3 WO 2006066214 A3 WO2006066214 A3 WO 2006066214A3 US 2005045954 W US2005045954 W US 2005045954W WO 2006066214 A3 WO2006066214 A3 WO 2006066214A3
Authority
WO
WIPO (PCT)
Prior art keywords
yersinia pestis
flagellin
immunotherapy
flagellin adjuvant
fusion protein
Prior art date
Application number
PCT/US2005/045954
Other languages
French (fr)
Other versions
WO2006066214A2 (en
Inventor
Steven B Mizel
Anna Nichole Honko
Original Assignee
Univ Wake Forest Health Sciences
Steven B Mizel
Anna Nichole Honko
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Wake Forest Health Sciences, Steven B Mizel, Anna Nichole Honko filed Critical Univ Wake Forest Health Sciences
Priority to AU2005316265A priority Critical patent/AU2005316265B2/en
Priority to EP05854630A priority patent/EP1824510B1/en
Priority to CA2589553A priority patent/CA2589553C/en
Priority to CN200580045581.XA priority patent/CN101094685B/en
Priority to US11/793,159 priority patent/US7794731B2/en
Priority to JP2007547004A priority patent/JP5094407B2/en
Publication of WO2006066214A2 publication Critical patent/WO2006066214A2/en
Publication of WO2006066214A3 publication Critical patent/WO2006066214A3/en
Priority to US12/837,223 priority patent/US8198424B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0291—Yersinia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A61K2039/55594—Adjuvants of undefined constitution from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/806—Antigenic peptides or proteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/825—Bacteria

Abstract

The invention provides a fusion protein comprising a flagellin adjuvant and a Yersinia pestis antigen. Also provided are compositions comprising a flagellin adjuvant and a Yersinia pestis antigen. The invention also discloses methods of making a fusion protein comprising a flagellin adjuvant and a Yersinia pestis antigen. The invention further provides pharmaceutical formulations and methods for inducing an immune response against Yersinia pestis.
PCT/US2005/045954 2004-12-16 2005-12-16 Use of flagellin in the immunotherapy of yersinia pestis WO2006066214A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
AU2005316265A AU2005316265B2 (en) 2004-12-16 2005-12-16 Use of flagellin in the immunotherapy of Yersinia pestis
EP05854630A EP1824510B1 (en) 2004-12-16 2005-12-16 Use of flagellin in the immunotherapy of yersinia pestis
CA2589553A CA2589553C (en) 2004-12-16 2005-12-16 Use of flagellin in the immunotherapy of yersinia pestis
CN200580045581.XA CN101094685B (en) 2004-12-16 2005-12-16 The purposes of flagellin in the immunotherapy of Yersinia pestis
US11/793,159 US7794731B2 (en) 2004-12-16 2005-12-16 Use of flagellin in the immunotherapy of Yersinia pestis
JP2007547004A JP5094407B2 (en) 2004-12-16 2005-12-16 Use of flagellin in immunotherapy of Yersinia pestis
US12/837,223 US8198424B2 (en) 2004-12-16 2010-07-15 Use of flagellin in the immunotherapy of Yersinia pestis

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US63663504P 2004-12-16 2004-12-16
US60/636,635 2004-12-16
US70960905P 2005-08-19 2005-08-19
US60/709,609 2005-08-19

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US11/793,159 A-371-Of-International US7794731B2 (en) 2004-12-16 2005-12-16 Use of flagellin in the immunotherapy of Yersinia pestis
US12/837,223 Division US8198424B2 (en) 2004-12-16 2010-07-15 Use of flagellin in the immunotherapy of Yersinia pestis

Publications (2)

Publication Number Publication Date
WO2006066214A2 WO2006066214A2 (en) 2006-06-22
WO2006066214A3 true WO2006066214A3 (en) 2007-03-22

Family

ID=36588637

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2005/045954 WO2006066214A2 (en) 2004-12-16 2005-12-16 Use of flagellin in the immunotherapy of yersinia pestis
PCT/US2005/045833 WO2006081007A2 (en) 2004-12-16 2005-12-16 Use of flagellin in tumor immunotherapy

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/US2005/045833 WO2006081007A2 (en) 2004-12-16 2005-12-16 Use of flagellin in tumor immunotherapy

Country Status (6)

Country Link
US (3) US7794731B2 (en)
EP (2) EP1824510B1 (en)
JP (2) JP5094407B2 (en)
AU (2) AU2005325715B2 (en)
CA (2) CA2589553C (en)
WO (2) WO2006066214A2 (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005026375A2 (en) 2003-05-22 2005-03-24 Fraunhofer Usa, Inc. Recombinant carrier molecule for expression, delivery and purification of target polypeptides
WO2005077408A2 (en) * 2004-02-06 2005-08-25 Vaxinnate Corporation Compositions of pamps and listeria monocytogenes and methods of use
US20090162400A1 (en) * 2004-12-21 2009-06-25 Powell Thomas J Compositions of influenza viral proteins and methods of use thereof
US8007812B2 (en) * 2004-12-22 2011-08-30 Cleveland Clinic Foundation Flagellin related polypeptides and uses thereof
BRPI0606479A (en) 2005-01-19 2008-03-11 Vaxinnate Corp compositions; fusion proteins; polypeptides; and methods for stimulating an immune response in an individual
GB2448255A (en) * 2005-12-01 2008-10-08 Trinity College Dublin Compositions and methods relating to treatment of cancer and infectious diseases
WO2007078879A2 (en) * 2005-12-21 2007-07-12 Vaxinnate Corporation Lipopeptide compositions and methods of use thereof
CN106237316A (en) 2006-03-07 2016-12-21 法克斯因内特公司 The compositions comprising hemagglutinin, the method manufacturing it and the method using it
US10174100B1 (en) * 2006-11-06 2019-01-08 Microvax, Llc Multivalent DNA composition for Yersinia pestis
CA2692933C (en) 2007-07-11 2016-10-18 Fraunhofer Usa, Inc. Yersinia pestis antigens, vaccine compositions, and related methods
WO2009016639A2 (en) * 2007-08-02 2009-02-05 Biondvax Pharmaceuticals Ltd. Multimeric multiepitope influenza vaccines
WO2009073133A1 (en) * 2007-11-29 2009-06-11 Vaxinnate Corporation Compositions of toll-like receptor agonists and papillomavirus antigens and uses thereof
AU2009236585B2 (en) * 2008-04-18 2013-03-07 Vaxinnate Corporation Deletion mutants of flagellin and methods of use
BRPI0911604A2 (en) * 2008-04-25 2015-12-15 Inst Systems Biology flagellin polypeptide vaccines
JP5756750B2 (en) * 2008-06-25 2015-07-29 インセルム（インスティチュート ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル） Novel immunoadjuvant compounds based on flagellin and uses thereof
EP2320948B1 (en) 2008-08-01 2013-03-06 Cleveland Biolabs, Inc. Methods for treating reperfusion injuries
KR20120129893A (en) * 2010-01-06 2012-11-28 백시네이트 코포레이션 Methods and compositions for providing protective immunity in the elderly
US9872895B2 (en) 2010-09-24 2018-01-23 Emory University TLR5 ligands, therapeutic methods, and compositions related thereto
WO2012054693A1 (en) * 2010-10-22 2012-04-26 Trudeau Institute Uses of yersinia yope peptide, gene, and subparts thereof as a plague vaccine component and assays for yersinia pestis-specific t cells
EP2663367A4 (en) 2011-01-10 2014-08-06 Cleveland Biolabs Inc Use of toll-like receptor agonist for treating cancer
CN103517713A (en) 2011-02-22 2014-01-15 彼昂德瓦克斯医药有限公司 Multimeric multiepitope polypeptides in improved seasonal and pandemic influenza vaccines
GB201119999D0 (en) * 2011-11-20 2012-01-04 Glaxosmithkline Biolog Sa Vaccine
US8932598B2 (en) 2012-08-28 2015-01-13 Vaxinnate Corporation Fusion proteins and methods of use
CN103041386B (en) * 2012-11-08 2013-11-13 中国科学院海洋研究所 Application of vibrio anguillarum recombinant protein
MX2017001279A (en) 2014-07-30 2017-08-07 Cleveland Biolabs Inc Flagellin compositons and uses.
EP3206708B1 (en) 2014-10-16 2022-11-02 Cleveland Biolabs, Inc. Methods and compositions for the treatment of radiation-related disorders
WO2018088933A1 (en) * 2016-11-14 2018-05-17 Limited Liability Company "Panacela Labs" Anti-tumor effects of a viral vector encoding a toll-like receptor and a toll-like receptor agonist
WO2020110154A1 (en) * 2018-11-30 2020-06-04 Bharat Biotech International Limited A chimeric therapeutic vaccine
WO2020140973A1 (en) * 2019-01-03 2020-07-09 Nanjing Legend Biotech Co., Ltd. Modified immune cells expressing flagellin polypeptide

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5985285A (en) * 1995-03-13 1999-11-16 The Secretary Of State For Defence In Her Britanic Majesty's Government Of The United Kingdom Of Great Britain And Northern Ireland Vaccines for plague

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3787820T2 (en) * 1986-03-11 1994-04-28 Shionogi & Co DNA coding for flagellin and vector containing it.
ATE121782T1 (en) 1988-05-05 1995-05-15 Praxis Biolog Inc RECOMBINANT VACCINE OF FLAGELLIN.
US6130082A (en) * 1988-05-05 2000-10-10 American Cyanamid Company Recombinant flagellin vaccines
US5618533A (en) * 1992-02-11 1997-04-08 Yale University Flagellin-based polypeptides for the diagnosis of lyme disease
US5888810A (en) * 1993-11-12 1999-03-30 The United States Of America As Represented By The Secretary Of Agriculture Campylobacteri jejuni flagellin-escherichia coli LT-B fusion protein
US6638510B1 (en) * 1994-09-08 2003-10-28 Board Of Trustees Of Michigan State University Recombinant plasmid and a method of controlling the effects of Yersinia pestis
US6211159B1 (en) * 1997-04-11 2001-04-03 University Of Toronto Flagellin gene, FlaC of campylobacter
US6706522B1 (en) * 1999-09-30 2004-03-16 Wisconsin Alumni Research Foundation Plasmid DNA from Yersinia pestis
US20030175287A1 (en) * 2001-01-03 2003-09-18 Yale University Innate immune system-directed vaccines
DE60141773D1 (en) * 2001-04-20 2010-05-20 Inst Systems Biology GREAT SIMILAR RECEPTOR 5-LIGANDS AND USE PROCESS
EP1453471B1 (en) * 2001-11-07 2011-01-05 Mannkind Corporation Expression vectors encoding epitopes of antigens and methods for their design
EP1536832A2 (en) * 2002-09-03 2005-06-08 Fondation Eurovacc Flagellin peptides as adjuvants for vaccines
ATE518881T1 (en) * 2004-12-02 2011-08-15 Csir GRAMPOSITIVE BACTERIAL CELLS CONTAINING A DISRUPTIVE FLAGELLIN, FLAGELLIN-BASED FUSION PROTEINS AND THEIR USE FOR REMOVAL OF METAL IONS FROM A LIQUID
JP4502402B2 (en) 2005-06-09 2010-07-14 パイオニア株式会社 Information recording medium
WO2007125535A1 (en) 2006-05-01 2007-11-08 Biondvax Pharmaceuticals Ltd. Recombinant flagellin gene and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5985285A (en) * 1995-03-13 1999-11-16 The Secretary Of State For Defence In Her Britanic Majesty's Government Of The United Kingdom Of Great Britain And Northern Ireland Vaccines for plague

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CUADROS C. ET AL.: "Flagellin fusion proteins as adjuvants or vaccines induce specific immune responses", INFECT. IMMUN., vol. 72, no. 5, May 2004 (2004-05-01), pages 2810 - 2816, XP002392967 *
EAVES-PYLES T.D. ET AL.: "Salmonella flagellin-dependent proinflammatory responses are localized to the conserved amino and carboxyl regions of the protein", J. IMMUNOL., vol. 167, 2001, pages 7009 - 7016, XP002341395 *

Also Published As

Publication number Publication date
EP1824510A2 (en) 2007-08-29
EP1824510A4 (en) 2008-11-05
US7794731B2 (en) 2010-09-14
EP1827489B1 (en) 2012-10-31
US20080220011A1 (en) 2008-09-11
JP5094407B2 (en) 2012-12-12
US8198424B2 (en) 2012-06-12
EP1827489A4 (en) 2008-11-05
EP1824510B1 (en) 2012-10-31
AU2005316265B2 (en) 2010-12-23
WO2006081007A2 (en) 2006-08-03
AU2005325715A1 (en) 2006-08-03
CA2589553C (en) 2014-02-18
AU2005325715B2 (en) 2011-10-06
AU2005316265A1 (en) 2006-06-22
US20080124361A1 (en) 2008-05-29
CA2589556A1 (en) 2006-08-03
CA2589553A1 (en) 2006-06-22
US20100285048A1 (en) 2010-11-11
JP2008523818A (en) 2008-07-10
EP1827489A2 (en) 2007-09-05
JP2008523819A (en) 2008-07-10
WO2006081007A3 (en) 2006-11-02
WO2006066214A2 (en) 2006-06-22

Similar Documents

Publication Publication Date Title
WO2006066214A3 (en) Use of flagellin in the immunotherapy of yersinia pestis
WO2006041933A3 (en) Improved vaccines
WO2006051110A3 (en) Stable formulations of insulinoptropic peptides
WO2007103048A3 (en) Tlr agonist (flagellin)/cd40 agonist/antigen protein and dna conjugates and use thereof for inducing synergistic enhancement in immunity
EA200802170A1 (en) LYOPHILIZED COMPOSITION OF THERAPEUTIC PEPTIDE ANTIBODY
WO2006126981A3 (en) Compositions and methods for mucosal vaccination
WO2008130382A3 (en) Fusion proteins comprising an anti -inflammatory cytokine and an antigen for treatment of immune disorders
WO2004075829A3 (en) Adjuvanted influenza vaccine
WO2007049155A3 (en) Compositions comprising yersinia pestis antigens
WO2005105139A3 (en) Mage-3 and ny-eso-1 based polyvalent vaccine for cancer immunotherapy
IL163812A (en) Immunizing composition, antigenic product and isolated antigenic peptide for inducing an immune response against beta-secretase cleavage site of amyloid the precursor protein
WO2007016185A3 (en) Mono-and bi-functional antibody conjugates as effective adjuvants of protein vaccination
WO2008054535A3 (en) Novel influenza m2 vaccines
WO2007078879A3 (en) Lipopeptide compositions and methods of use thereof
EP1858532A4 (en) Compositions and methods for less immunogenic protein formulations
WO2005007673A3 (en) Immunogenic peptides
WO2006062917A3 (en) Alpha thymosin peptides as cancer vaccine adjuvants
WO2008089074A3 (en) Fusion proteins comprising the tumor rejection antigens ny-eso-1 and lage-1
WO2005028618A3 (en) Immunogenic compositions for streptococcus agalactiae
WO2006007555A3 (en) Rotavirus antigens
WO2006064378A3 (en) Adjuvant activity of gastrointestinal peptides
EP1583506A3 (en) Eye-drop vaccine containing copolymer 1 for therapeutic immunization
AU2003203002A1 (en) Polymeric conjugates for delivery of mhc-recognized epitopes via peptide vaccines
WO2007146359A3 (en) Sea lice antigen vaccines
WO2006007366A3 (en) SKIN IMMUNIZATION USING LT-STa FUSION PROTEINS

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2589553

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2005316265

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2007547004

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2005854630

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 200580045581.X

Country of ref document: CN

ENP Entry into the national phase

Ref document number: 2005316265

Country of ref document: AU

Date of ref document: 20051216

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005316265

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2005854630

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 11793159

Country of ref document: US